Interviews

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.

Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses two important trials in breast cancer looking at extended hormonal therapy.

Implementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.

Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.